跳至主要内容
临床试验/NL-OMON30362
NL-OMON30362已完成4 期

IMPROVED: Induction therapy with Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic Disease;A randomized clinical trial in patients with recent-onset arthritis to compare the efficacy of DMARD combination therapy including prednisone with combination therapy including adalimumab, a TNF-blocking agent. - IMPROVED

eids Universitair Medisch Centrum0 个研究点目标入组 610 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
610

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. minimum age of 18 years
  • 2. at least one swollen joint
  • 3. at least one other painful joint
  • 4. symptom duration shorter than 2 years
  • 5. diagnosis rheumatoid arthritis according to the ACR classification criteria or
  • 6. diagnosis undifferentiated arthritis, suspected for rheumatoid arthritis by the rheumatologist, as no classification criteria exist.
  • 7. patients naive for treatment with corticosteroids or disease modifying anti-rheumatic drugs (DMARDs).

排除标准

  • 1. previous therapy with DMARDs or with corticosteroids (exception: one dose of parenteral corticosteroids within the last 6 months, but not within the last 2 months, or an oral dose of prednisone of =<10 mg/day for =< 2 weeks within the same period allowed).
  • 2. pregnancy or wish to become pregnant during the study, or childbearing potential without adequate contraception
  • 3. concomitant treatment with another experimental drug
  • 4. history or presence of malignancy within the last five years
  • 5. bone marrow hypoplasia
  • 6. elevated hepatic enzyme levels (ASAT, ALAT > 3 times normal value)
  • 7. serum creatinine level > 150 umol/l or estimated creatinine clearance of < 75%
  • 8. uncontrolled diabetes mellitus (according to the rheumatologist)
  • 9. uncontrolled hypertension or moderate to severe heart failure (NYHA class III/IV)
  • 10. alcohol or drug abuse
  • 11. history of infected joint prothesis within the previous 3 months
  • 12. serious infections, such as hepatitis, pneumonia, pyelonephritis in the previous 3 months
  • 13. chronic infectious disease such as chronic renal infection, chronic chest infection with bronchiectasis or sinusitis
  • 14. history of active tuberculosis requiring treatment within previous 3 years, or signs and symptoms of latent infection with tuberculosis, based on medical history, physical examination, tuberculin (PPD) skin test or chest radiograph (see 9.3.1).
  • 15. history of other granulomatous infections as histoplasmosis or coccidiomycosis
  • 16. evidence of active cytomegalovirus, active pneumocystis carinii, active aspergillosis, or drug resistant atypical mycobacterium infection
  • 17. history of opportunistic infections such as herpes zoster within previous 2 months.
  • 18. history of active hepatitis B infection or evidence of a latent infection (see 9.3.1).
  • 19. documented HIV infection, AIDS related complex (ARC) or AIDS.
  • 20. history of lymphoproliferative disease including lymphoma or signs suggestive of possible lymphoproliferative disease.
  • 21. Multiple sclerosis or neurological symptoms suspect for demyelinising disease.
  • 22. Hypersensitivity to human immunoglobuline or other constituents of adalimumab

研究者

相似试验